History of Cardioxyl
2005
Cardioxyl Pharmaceuticals was founded in Maryland in 2005 with an exclusive license to technology developed by David Kass, M.D., Nazareno Paolloci, M.D., Ph.D., and John Toscano, PhD. at Johns Hopkins University.
2006
Cardioxyl raised a $14.5 million Series A financing in November from the Aurora Funds and New Enterprise Associates.
2007
The company established its proprietary nitroxyl donor chemistry platform and initiated the pre-clinical development of CXL-1020.
2008
Cardioxyl completed the pre-clinical development of CXL-1020, intended for the treatment of Acute Decompensated Heart Failure, and initiated the development of nitroxyl donors for additional indications.
Chris Kroeger, M.D. joined the company as President and Chief Executive Officer
Chris Kroeger, M.D. joined the company as President and Chief Executive Officer
2009
Cardioxyl initiated a Phase I/IIa clinical trial for CXL-1020.
John Reardon, Ph.D. joined the company as its Chief Scientific Officer.
Cardioxyl closed on an additional $9MM dollars in venture financing.
John Reardon, Ph.D. joined the company as its Chief Scientific Officer.
Cardioxyl closed on an additional $9MM dollars in venture financing.
2010
Cardioxyl concluded its Phase I/IIa clinical trial for CXL-1020.
Cardioxyl initiated a Phase IIa clinical trial for CXL-1020.
Cardioxyl closed on an additional $15MM in venture financing.
Cardioxyl initiated a Phase IIa clinical trial for CXL-1020.
Cardioxyl closed on an additional $15MM in venture financing.
